These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 20202195)

  • 1. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
    Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
    J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
    Sato A; Asano T; Ito K; Asano T
    J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
    Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
    PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.